These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 20807330)
41. Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism. Yamaguchi K; Ishikawa T; Chiba K; Fujisawa M Andrologia; 2011 Feb; 43(1):52-6. PubMed ID: 21219383 [TBL] [Abstract][Full Text] [Related]
42. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Karazindiyanoğlu S; Cayan S Aging Male; 2008 Sep; 11(3):146-9. PubMed ID: 18821291 [TBL] [Abstract][Full Text] [Related]
43. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125 [TBL] [Abstract][Full Text] [Related]
44. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Garcia JA; Sanchez PE; Fraile C; Escovar P Andrologia; 2011 Oct; 43(5):293-6. PubMed ID: 21919947 [TBL] [Abstract][Full Text] [Related]
45. [Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism]. Amano T Clin Calcium; 2013 Aug; 23(8):1179-84. PubMed ID: 23892219 [TBL] [Abstract][Full Text] [Related]
46. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Morrison BF; Reid M; Madden W; Burnett AL Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509 [TBL] [Abstract][Full Text] [Related]
48. Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. Almehmadi Y; Yassin AA; Nettleship JE; Saad F Arab J Urol; 2016 Mar; 14(1):31-6. PubMed ID: 26966591 [TBL] [Abstract][Full Text] [Related]
49. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859 [TBL] [Abstract][Full Text] [Related]
50. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499 [TBL] [Abstract][Full Text] [Related]
51. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men. Behre HM; Heinemann L; Morales A; Pexman-Fieth C Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063 [TBL] [Abstract][Full Text] [Related]
52. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589 [TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of short-acting testosterone ointment (Glowmin) for late-onset hypogonadism in accordance with testosterone circadian rhythm. Amano T; Iwamoto T; Sato Y; Imao T; Earle C Aging Male; 2018 Sep; 21(3):170-175. PubMed ID: 29734846 [TBL] [Abstract][Full Text] [Related]
54. Oral testosterone replacement in Korean patients with PADAM. Hong JH; Ahn TY Aging Male; 2002 Mar; 5(1):52-6. PubMed ID: 12040976 [TBL] [Abstract][Full Text] [Related]
55. [Late-onset hypogonadism in men: uncertain disease entity and reservations regarding treatment with testosterone]. Nieuwenhuijzen Kruseman AC Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1925-8. PubMed ID: 16999276 [TBL] [Abstract][Full Text] [Related]
56. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men. Berg G; Schreier L; Geloso G; Otero P; Nagelberg A; Levalle O Horm Metab Res; 2002 Feb; 34(2):87-92. PubMed ID: 11972293 [TBL] [Abstract][Full Text] [Related]
57. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347 [TBL] [Abstract][Full Text] [Related]
58. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Traish AM; Haider A; Doros G; Saad F Int J Clin Pract; 2014 Mar; 68(3):314-29. PubMed ID: 24127736 [TBL] [Abstract][Full Text] [Related]
59. Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men. Maggi M; Heiselman D; Knorr J; Iyengar S; Paduch DA; Donatucci CF J Sex Med; 2016 Aug; 13(8):1220-6. PubMed ID: 27436077 [TBL] [Abstract][Full Text] [Related]
60. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism. Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]